Metraipolis › archive › dc_8fbe7019d13a
An enhanced three-stage design with trend analysis for allergen immunotherapy trials — Europe PMC PMID:37708124
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37708124
- DOI
- 10.1371/journal.pone.0291533
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:26:55.078Z
- SHA-256 of the archived text
aed123254686e258690d6f6a17156078e09b061633a990a2cc1397c4f1e86f23- Stable URL of this page
https://metraipolis.com/documento/dc_8fbe7019d13a
How to cite
An enhanced three-stage design with trend analysis for allergen immunotherapy trials — Europe PMC PMID:37708124 — Europe PMC (en), https://europepmc.org/article/MED/37708124 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_8fbe7019d13a (Metraipolis archive dc_8fbe7019d13a, sha256 aed123254686e258690d6f6a17156078e09b061633a990a2cc1397c4f1e86f23)
BibTeX
@misc{dc8fbe7019d13a,
title = {An enhanced three-stage design with trend analysis for allergen immunotherapy trials — Europe PMC PMID:37708124},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37708124},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_8fbe7019d13a; sha256 aed123254686e258690d6f6a17156078e09b061633a990a2cc1397c4f1e86f23},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37708124. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
We previously introduced a three-stage design and associated end-of-stage analyses for allergen immunotherapy (AIT) trials. End-of-stage differences alone may not provide a fuller picture of Stages 2 and 3 effects because they may depend upon stage-specific durations. Therefore, we introduce an additional trend analysis to evaluate the difference in progression curves of two groups over the entire stage. Results from such analysis are used to inform persistence of end-of-stage benefit and thus provide evidence for stagewise effects beyond the study periods. We jointly apply end-of-stage and trend analyses to support the enhanced three-stage design to determine treatment response over time and sustained response to AIT. A simulation study was performed to illustrate the statistical properties (bias and power) of trend analyses under varying statistical missing mechanisms and effect sizes. The extent of bias depended on the missing mechanism and magnitude. Powers were largely driven by effect and sample sizes as well as pre-specified success margins, particularly of relative trend. As an illustration, assuming relative treatment differences of 25-30%, stagewise dropout rate of 15%, and parallel outcome progressions, a sample size of 200 per group may achieve 97% power to demonstrate a treatment effect and 53% power to demonstrate a sustained effect post-treatment. Trend analysis supplements the end-of-stage analysis to enhance the statistical claims of stagewise effects. Inferential statistics support our proposed trend analysis for evaluating benefits of AIT over time and inform clinical understanding and decisions. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-09-14). Identificativi: PMID 37708124 · PMCID PMC10501591 · DOI 10.1371/journal.pone.0291533. Descrittori MeSH principali: Desensitization, Immunologic; Dietary Supplements. Pagina: https://europepmc.org/article/MED/37708124 — https://doi.org/10.1371/journal.pone.0291533. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:59:26.193Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.